TY - JOUR
T1 - Reliable stability prediction to manage research or marketed vaccines and pharmaceutical products. “Avoid any doubt for the end-user of vaccine compliance at time of administration”
AU - Brass, Olivier
AU - Claudy, Pierre
AU - Grenier, Emmanuel
N1 - Publisher Copyright:
© 2022
PY - 2022/4/25
Y1 - 2022/4/25
N2 - A major challenge for the pharmaceutical/vaccine industry is to anticipate and test/control product stability, regardless of the time/temperature profile of the product, from release to administration. Current empirical stability protocols performed to ensure product stability remain limited to the prediction of product stability in a thermal excursion (cold chain break) during their long-term storage. As recently recommended by the World Health Organization, mathematical models can be used for shelf-life and stability predictions. Therefore, various approaches have been published with good performance for simple chemical reactions. However, for biomolecules/vaccines, more complex reaction profiles require more complex models to predict their stability with a good level of confidence. This complexity constitutes a real scientific challenge because the number of model parameters increases with model complexity and need to be balanced with the limited number and quality of the available experimental data. We have developed a dedicated method/software based on different vaccines/pharmaceutical case studies. This predictive method considers phenomenological models, five levels of model confidence assessment, predictive quality value and simulated designs of experiment to improve and define the limits within which the prediction models can be used, and to increase model/prediction confidence to the required regulatory and scientific levels. This artificial intelligence system should help to avoid any doubt of stability at time of vaccine injection.
AB - A major challenge for the pharmaceutical/vaccine industry is to anticipate and test/control product stability, regardless of the time/temperature profile of the product, from release to administration. Current empirical stability protocols performed to ensure product stability remain limited to the prediction of product stability in a thermal excursion (cold chain break) during their long-term storage. As recently recommended by the World Health Organization, mathematical models can be used for shelf-life and stability predictions. Therefore, various approaches have been published with good performance for simple chemical reactions. However, for biomolecules/vaccines, more complex reaction profiles require more complex models to predict their stability with a good level of confidence. This complexity constitutes a real scientific challenge because the number of model parameters increases with model complexity and need to be balanced with the limited number and quality of the available experimental data. We have developed a dedicated method/software based on different vaccines/pharmaceutical case studies. This predictive method considers phenomenological models, five levels of model confidence assessment, predictive quality value and simulated designs of experiment to improve and define the limits within which the prediction models can be used, and to increase model/prediction confidence to the required regulatory and scientific levels. This artificial intelligence system should help to avoid any doubt of stability at time of vaccine injection.
KW - Confidence levels
KW - Modeling
KW - New software
KW - Prediction
KW - Regulatory requirements
KW - Vaccine stability DoE
UR - https://www.scopus.com/pages/publications/85126311953
U2 - 10.1016/j.ijpharm.2022.121604
DO - 10.1016/j.ijpharm.2022.121604
M3 - Article
C2 - 35219824
AN - SCOPUS:85126311953
SN - 0378-5173
VL - 618
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 121604
ER -